Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany rak jelita grubego w stadium IV (zaawansowany)
- •Widoczny guz, który można zmierzyć na badaniach obrazowych
- •Planowane leczenie chemioterapią pierwszej linii
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-2)
- •Odpowiednie wyniki badań krwi: liczba neutrofili, płytki krwi, hemoglobina
- •Dobra funkcja wątroby i nerek
- •Nie w ciąży i nie karmiące piersią
- •Zgoda na stosowanie antykoncepcji podczas badania (osoby w wieku rozrodczym)
✗ Disqualifies
- •Całkowite usunięcie jelita grubego
- •Rozpoznanie zespołu Cockayne'a
- •Przyjmowanie leku disulfiram
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Virginia Cancer Institute (VCI)
Richmond, United States
Virginia Commonwealth University
Richmond, United States
Trial contact
Massey IIT Research Operations
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.